Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

This is a Phase 3, multicenter, open-label, single-arm additional study to evaluate the efficacy of intrathecal KP-100IT in patients with acute spinal cord injury. Eligible patients will receive KP-100 0.6 mg/body by intrathecal administration once per week for a total of 5 doses and will be followed for approximately 24 weeks after the first dose.

Inclusion Criteria: * Patients whose AIS grade is A at 72 hours (± 6 hours) after injury * age: 18 years to 89 years * MRI imaging and other tests confirm the continuity of the spinal cord Exclusion Criteria: * The injury site is C1-C2 or C2-C3 * The patient with a spinal crd compression rate of 70% or higher. * The patient in whom a spinal cord rupture is strongle suspected. * The patient cannot start rehabilitation necessary for recovery of function at an early stage. * External trauma or concurrent organ injury. * High dose steroid therapy administered for the treatment of spinal cord injury * History or concurrent presence of malignant tumor. * It is inappropriate for the subject to be included in the study, in the opinion of the investigator.